Sign In
23 Aug 2018 12:50
23 August 2018
Â
Â
Deltex Medical Group plc
("Deltex Medical" or the "Company")
Â
Â
Director Dealing
Â
Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring ("ODM"), was informed yesterday that Nigel Keen, Chairman of the Company, purchased 2,000,000 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at a price of 0.8 pence per Ordinary Share and 1,000,000 Ordinary Shares at a price of 0.85 pence per Ordinary Share on 21 August 2018. On 22 August 2018, 1,000,000 Ordinary Shares at a price of 0.9 pence per Ordinary Share were also purchased.
Â
Following these transactions, Mr Keen's beneficial ownership is 52,223,410 Ordinary Shares, representing approximately 10.6 per cent. of Deltex Medical's issued ordinary share capital.
Â
Mr Keen also transferred 6,000,000 Ordinary Shares into the Imperialise Limited Pension Fund on 23 August 2018. Mr Keen is the principal beneficiary of this fund and following this transaction, his beneficial interest in the Company remains unchanged from that stated above.
Â
For further information, please contact:-
Â
Deltex Medical Group plc | 01243 774 837 investorinfo@deltexmedical.com | |
Nigel Keen, Chairman | ||
Andy Mears, Chief Executive | ||
Jonathan Shaw, Group Finance Director | ||
Nominated Adviser & Broker | ||
Arden Partners plc  | 020 7614 5900 | |
Chris Hardie Ciaran Walsh | ||
Joint Broker | ||
Turner Pope Investments (TPI) Ltd | 0203 621 4120 info@turnerpope.com | |
Andy Thacker | ||
 Financial Public Relations | ||
IFC Advisory  | 0203 934 6630 | |
Tim Metcalfe Graham Herring Heather Armstrong | ||
Â
Â
Notes for Editors
Â
Deltex Medical manufactures and markets haemodynamic monitoring technologies. Deltex Medical's proprietary ODM (TrueVueTMÂ Doppler) is the only technology to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Deltex has been the only group in the enhanced haemodynamic space to build a robust and credible evidence base proving the clinical and economic benefits of its core technology, TrueVueTMÂ Doppler, which is proven to reduce complications suffered by patients after surgery and save hospitals the costs of treating those complications.
Â
Deltex Medical's TrueVueTMÂ System on the CardioQ-ODM+ monitor platform also now provides clinicians with two further advanced haemodynamic monitoring technologies. High Definition Impedance Cardiography (TrueVueTM Impedance) is an entirely non-invasive monitoring technology which creates an electrical field across the chest and measures the disruption to this field when the heart pumps blood. Pulse Pressure Waveform Analysis(TrueVueTM Pressurewave) uses peripheral blood pressure signal analysis to give doctors information on changes in the circulation and is particularly suited to monitoring lower risk or haemodynamically stable patients.
Â
Group goal
Â
Haemodynamic management is now becoming widely accepted as an important major new medical modality. Consequently, the Group's focus is on maximising value from the opportunities presented, as enhanced haemodynamic management is adopted into routine clinical practice around the world. The Group aims to provide clinicians with a single platform, a 'haemodynamic workstation', which offers them a range of technologies from simple to sophisticated to be deployed according to the patient's condition as well as the skill and expertise of the user. Doing this will enable the Group to partner healthcare providers to support modern haemodynamic management across the whole hospital.
Â
The Group is currently in the implementation phase of achieving this goal in a number of territories worldwide, operating directly in the UK, USA, Spain and Canada and through distribution arrangements in a further 30 countries.
Â
Note: This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them.
  1  | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)  | Names | Nigel Keen - Chairman | ||||
2 Â | Reason for the notification | |||||
a)  | Position/status  | See 1(a) above for position - classified as a PDMR of Deltex Medical | ||||
b)  | Initial notification /Amendment  | Initial | ||||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)  | Name  | Deltex Medial Group plc  | ||||
b) Â | LEI | 213800XN34P6LI8J6M39 | ||||
4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)  | Description of the financial instrument, type of instrument  | Ordinary shares of 1 penny each ("Ordinary Shares") | ||||
b) | Identification code  | GB0059337583 | ||||
c)  | Nature of the transaction  | Purchase of Ordinary Shares  | ||||
d) Â | Price(s) and volume(s) |
| ||||
d)  | Aggregated information - Aggregated volume - Price | 2,000,0000.8 pence | ||||
e)  | Date of the transaction | 21 August 2018 | ||||
f) Â | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Â
  1  | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)  | Names | Nigel Keen - Chairman | ||||
2 Â | Reason for the notification | |||||
a)  | Position/status  | See 1(a) above for position - classified as a PDMR of Deltex Medical | ||||
b)  | Initial notification /Amendment  | Initial | ||||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)  | Name  | Deltex Medial Group plc  | ||||
b) Â | LEI | 213800XN34P6LI8J6M39 | ||||
4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)  | Description of the financial instrument, type of instrument  | Ordinary shares of 1 penny each ("Ordinary Shares") | ||||
b) | Identification code  | GB0059337583 | ||||
c)  | Nature of the transaction  | Purchase of Ordinary Shares  | ||||
d) Â | Price(s) and volume(s) |
| ||||
d)  | Aggregated information - Aggregated volume - Price | 1,000,0000.85 pence | ||||
e)  | Date of the transaction | 21 August 2018 | ||||
f) Â | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Â
Â
  1  | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)  | Names | Nigel Keen - Chairman | ||||
2 Â | Reason for the notification | |||||
a)  | Position/status  | See 1(a) above for position - classified as a PDMR of Deltex Medical | ||||
b)  | Initial notification /Amendment  | Initial | ||||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)  | Name  | Deltex Medial Group plc  | ||||
b) Â | LEI | 213800XN34P6LI8J6M39 | ||||
4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)  | Description of the financial instrument, type of instrument  | Ordinary shares of 1 penny each ("Ordinary Shares") | ||||
b) | Identification code  | GB0059337583 | ||||
c)  | Nature of the transaction  | Purchase of Ordinary Shares  | ||||
d) Â | Price(s) and volume(s) |
| ||||
d)  | Aggregated information - Aggregated volume - Price | 1,000,0000.9 pence | ||||
e)  | Date of the transaction | 22 August 2018 | ||||
f) Â | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Â
Â
Â
  1  | Details of the person discharging managerial responsibilities / person closely associated | |||||
a)  | Names | Nigel Keen - Chairman | ||||
2 Â | Reason for the notification | |||||
a)  | Position/status  | See 1(a) above for position - classified as a PDMR of Deltex Medical | ||||
b)  | Initial notification /Amendment  | Initial | ||||
3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a)  | Name  | Deltex Medial Group plc  | ||||
b) Â | LEI | 213800XN34P6LI8J6M39 | ||||
4 Â | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)  | Description of the financial instrument, type of instrument  | Ordinary shares of 1 penny each ("Ordinary Shares") | ||||
b) | Identification code  | GB0059337583 | ||||
c)  | Nature of the transaction  | Share Transfer  | ||||
d) Â | Price(s) and volume(s) |
| ||||
d)  | Aggregated information - Aggregated volume - Price | 6,000,000Nil | ||||
e)  | Date of the transaction | 23 August 2018 | ||||
f) Â | Place of the transaction | Off market transaction | ||||
Â
Follow the stocks
